Compare HZO & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HZO | ANNX |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 788.1M | 873.3M |
| IPO Year | 1998 | 2020 |
| Metric | HZO | ANNX |
|---|---|---|
| Price | $52.45 | $4.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $30.00 | $16.50 |
| AVG Volume (30 Days) | 708.6K | ★ 2.6M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $2,309,288,000.00 | N/A |
| Revenue This Year | $3.67 | N/A |
| Revenue Next Year | $4.01 | $16,320.74 |
| P/E Ratio | $249.86 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.42 | $2.54 |
| 52 Week High | $52.50 | $7.18 |
| Indicator | HZO | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 78.25 | 36.25 |
| Support Level | $52.08 | N/A |
| Resistance Level | N/A | $5.63 |
| Average True Range (ATR) | 0.14 | 0.21 |
| MACD | -0.52 | -0.02 |
| Stochastic Oscillator | 86.90 | 29.18 |
MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S and international market.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.